Downloads

  1. Immune Reset In Rheumatology: Moving Beyond Disease Suppression Toward Durable Remission 8/18/2026

    EULAR 2026 highlighted growing momentum behind “immune reset,” an approach adapted from oncology that is quickly gaining traction in autoimmune rheumatic diseases.

  2. Closing The Loop Between AI And Experimental Biology 8/17/2026

    We caught up with Rosie Rodriguez, Ph.D., president of growth at Relation, to discuss AI’s place in accelerating discovery

  3. Beyond Apoptosis: Context Is The Target 8/17/2026

    Cells that evade apoptosis do not necessarily evade death; they may remain vulnerable to ferroptosis, pyroptosis, necroptosis, or another regulated cell death program.

  4. Alpha-Synuclein Is Not One Target 8/14/2026

    Alpha-synuclein is not one target, and a nanobody is not a smaller antibody with automatic access.

  5. Early Decisions That Shape Success In CNS Drug Development And Commercialization, Part 2 8/11/2026

    In part 2, Ginger continues to provide insights for R&D teams on CNS development and commercialization.

  6. The Body As A Bioreactor – Delivering The Vision 8/8/2026

    Making the body a bioreactor requires precise delivery to selected cells. See how lipid nanoparticles, manufacturing science, and biology are converging to overcome biological barriers and improve the targeting of advanced therapies.

  7. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

    Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

  8. Early Decisions That Shape Success In CNS Drug Development And Commercialization, Part 1 8/4/2026

    In part 1, we caught up with Ginger Johnson, SVP and neuroscience lead at Lumanity, to discuss how companies can connect the science to the realities of CNS drug development earlier

  9. The Changing Role Of Computational Mechanics In Drug Discovery 8/3/2026

    Computational models will never replace experimental biology, but their emerging role is different.

  10. Beyond Binder Design: Why AI's Next Frontier Is Designing Multispecific Antibodies 7/31/2026

    Many of the therapies with the greatest potential to improve patient outcomes are complex multispecifics, where the data simply doesn't exist.